Literature DB >> 24713269

Inactive fibrotic lesions versus pulmonary tuberculosis with negative bacteriology.

Jordi Solsona Peiró1, Maria Luiza de Souza Galvão2, Maria Neus Altet Gómez2.   

Abstract

This article analyzes the concept of inactive fibrotic lesions of presumed tuberculous origin (old healed tuberculosis), defined by radiological characteristics and a positive tuberculin skin test (TST), and we examine the evidence-based foundation for the indication of treatment of latent tuberculosis infection in these cases. We explore the risk of reactivation in older and recent literature, and the problems raised by the differential diagnosis with active tuberculosis with negative bacteriology. We also analyze data on the prevalence of fibrotic lesions in the recent literature. We examine the possible role of Interferon Gamma Release Assays (IGRAs) versus TST and other molecular antigen detection techniques in sputum that can aid in establishing the diagnosis and we discuss the current indications for chemoprophylaxis and the different options available. We propose diagnostic guidelines and therapeutic algorithms based on risk stratification by age and other factors in the management of radiological lesions that raise a differential diagnosis between fibrotic lesions and active pulmonary tuberculosis with negative bacteriology.
Copyright © 2013 SEPAR. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Factor de riesgo; Fibrotic lesion; Infección tuberculosa latente; Interferon Gamma Release Assay; Latent tuberculous infection; Lesión fibrótica; Old healed tuberculosis; Prueba de la tuberculina; Riesgo de reactivación; Risk factor; Risk of reactivation; Tuberculin skin test; Tuberculosis; Tuberculosis antigua curada

Mesh:

Substances:

Year:  2014        PMID: 24713269     DOI: 10.1016/j.arbres.2013.07.009

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  5 in total

1.  Policy and practice of programmatic management of latent tuberculosis infection in The Netherlands.

Authors:  Gerard de Vries; Rob van Hest; Marleen Bakker; Connie Erkens; Susan van den Hof; Wieneke Meijer; Karen Oud; Erika Slump; Jaap van Dissel
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2017-03-18

2.  Abnormalities suggestive of latent tuberculosis infection on chest radiography; how specific are they?

Authors:  Jonathan W Uzorka; Lucia J M Kroft; Jaap A Bakker; Erik W van Zwet; Erik Huisman; Corine Prins; Cornelis J van der Zwan; Tom H M Ottenhoff; Sandra M Arend
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-01-25

3.  Clinical profiles of subclinical disease among pulmonary tuberculosis patients: a prospective cohort study in South Korea.

Authors:  Jinsoo Min; Chaeuk Chung; Sung Soo Jung; Hye Kyeong Park; Sung-Soon Lee; Ki Man Lee
Journal:  BMC Pulm Med       Date:  2020-12-02       Impact factor: 3.317

4.  Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden.

Authors:  Narendran Gopalan; Vignes Anand Srinivasalu; Ponnuraja Chinnayan; Banurekha Velayutham; Adhin Bhaskar; Ramesh Santhanakrishnan; Thirumaran Senguttuvan; Sridhar Rathinam; Mahilmaran Ayyamperumal; Kumar Satagopan; Dhanalakshmi Rajendran; Tamizhselvan Manoharan; Sekar Lakshmanan; Paulkumaran Paramasivam; Dhanalakshmi Angamuthu; Mangalambal Ganesan; John Washington Easudoss Arockia; Ramesh Babu Venkatesan; Venkatesan Lakshmipathy; Shivakumar Shanmugham; Balaji Subramanyam; Shakila Shankar; Jawahar Mohideen Shaheed; Baskaran Dhanaraj; Narayanan Paranji Ramiyengar; Soumya Swaminathan; Padmapriyadarsini Chandrasekaran
Journal:  PLoS One       Date:  2021-09-20       Impact factor: 3.240

5.  Chest X-ray findings in drug-sensitive and drug-resistant pulmonary tuberculosis patients in Uganda.

Authors:  Anthony Oriekot; Senai Goitom Sereke; Felix Bongomin; Samuel Bugeza; Zeridah Muyinda
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.